These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196 [TBL] [Abstract][Full Text] [Related]
5. Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Wang X; Hui Y; Wang S; Hu X; Yu X; Wang W; Zhang X; Liu L J Pharm Pharm Sci; 2020; 23():451-461. PubMed ID: 33217255 [TBL] [Abstract][Full Text] [Related]
6. Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. Mori K; Kimura T; Onuma H; Kimura S; Yamamoto T; Sasaki H; Miki J; Miki K; Egawa S Prostate; 2017 Jul; 77(10):1144-1150. PubMed ID: 28557065 [TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. Soleimani M; Zou K; Sunderland K; Struss W; Eigl BJ; Nappi L; Kollmannsberger CK; Finch D; Noonan K; Vergidis J; Zulfiqar M; Chi KN; Khalaf DJ Eur J Cancer; 2021 Jul; 152():215-222. PubMed ID: 34130153 [TBL] [Abstract][Full Text] [Related]
9. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. Terada N; Maughan BL; Akamatsu S; Kobayashi T; Yamasaki T; Inoue T; Kamba T; Ogawa O; Antonarakis ES Int J Urol; 2017 Jun; 24(6):441-448. PubMed ID: 28455853 [TBL] [Abstract][Full Text] [Related]
10. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide. Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090 [TBL] [Abstract][Full Text] [Related]
11. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820 [TBL] [Abstract][Full Text] [Related]
12. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813 [TBL] [Abstract][Full Text] [Related]
15. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer. Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308 [TBL] [Abstract][Full Text] [Related]
16. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579 [TBL] [Abstract][Full Text] [Related]
17. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study. Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895 [TBL] [Abstract][Full Text] [Related]
18. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987 [TBL] [Abstract][Full Text] [Related]
19. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID; BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide. Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]